Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | TACR3 | P29371 | 1/20 | 0.32 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19756277 | 0.83 | DPP7 (0.36) | USP2TSHRTACR1TACR3PTGS1 | |
| SCHEMBL19756256 | 0.80 | ALDH1A1 (0.35) | USP2TSHR | |
| SCHEMBL20623017 | 0.76 | GRIA1 (0.37) | USP2TSHRTACR1TACR3 | |
| SCHEMBL22391540 | 0.74 | USP2 (0.32) | USP2TSHR | |
| SCHEMBL23520993 | 0.74 | USP2 (0.32) | USP2TSHR | |
| SCHEMBL20670295 | 0.73 | USP2 (0.33) | USP2TSHRKISS1R | |
| SCHEMBL20622994 | 0.73 | USP2 (0.33) | USP2TSHR | |
| SCHEMBL20670289 | 0.73 | USP2 (0.33) | USP2TSHRKISS1R | |
| SCHEMBL20622948 | 0.73 | USP2 (0.33) | USP2TSHR | |
| SCHEMBL22674736 | 0.72 | ECE1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11564974-B2 | Combination therapy with controlled-release CNP agonists | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2023-01-31 | — | — | US | disclosed |
| US-20210069339-A1 | CNP PRODRUGS | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2021-03-11 | — | — | US | disclosed |
| US-20200276270-A1 | Combination Therapy with Controlled-Release CNP Agonists | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069339-A1 | CNP PRODRUGS | NPPA, NPR1, NPR3 | USP2 1645/4885TSHR 1233/4885TACR1 64/4885 |
| US-20200276270-A1 | Combination Therapy with Controlled-Release CNP Agonists | CNP, NPR1, NGF | USP2 2073/4885TSHR 287/4885TACR1 137/4885 |
| US-11564974-B2 | Combination therapy with controlled-release CNP agonists | CNP, NPR1, NGF | USP2 2073/4885TSHR 287/4885TACR1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.